Autogen Limited - An Overview, Investee Profile: Alchemia, Bio Shares,The Deloitte Biotech Index
Australasian Biotechnology, Volume 9 Number 5, November/December 1999,pp. 250-263 Autogen Limited - An Overview, Investee Profile: Alchemia,BIO SHARES, The Deloitte Biotech Index Code Number: AU99014 AutogenLimited - An Overview Summary of Announcement Agreement in principlefor: i) a placement of 15% of Company's shares at 25 cents per share toMerck Lipha s.a. ii) Merck Lipha s.a. to fund Autogen's Human GeneticsProject conducted by International Diabetes Institute _ US$1 millionper annum for 6 years. iii) Jean-Noel Treilles, Chairman and ChiefExecutive Officer or Merck Lipha s.a., to be appointed a Director ofAutogen. Investee Profile: Alchemia Alchemia has attracted its thirdround of venture capital funding. The commitment of $4 million fromCoates Myer IIF Fund brings the amount of equity capital raised byAlchemia to $8 million. Alchemia is developing a novel technology thatenables the cost effective manufacture of carbohydrates employingpurely chemical synthetic methodology. The immediate commercialapplications of Alchemia's technology are in the areas ofpharmaceutical and nutraceutical development. BIO SHARES CoveringAustralian Biotechnology Stocks BIO SHARES The Deloitte Biotech Index AReview of Key Biotechnology Stocks Listed on the Australian StockExchange - December 1999 _ 1st Edition Summary The Deloitte BiotechIndex focuses exclusively on 29 listed biotechnology companies,excluding the "Blue Chip" healthcare companies found in the ASXHealthcare and Biotech Index. The biggest companies considered in theIndex are Biota, Cochlear, CSL, Novogen and Polartechnics. DeloitteBiotech Index results include: From January 1997 to October 1998, theNASDAQ Biotech Index, the ASX All Ordinaries Index, and the ASXHealthcare and Biotech Index performed similarly. Since October 1998,the largest part of the indice increases have occurred, led by theDeloitte Biotech Index and the NASDAQ Biotech Index. Newly listedbiotechnology stocks have generally been remarkably successful. Therapid evolution of the Australian biotechnology sector has seen biotechstocks outstrip the ASX All Ordinaries Index more than five-fold inDeloitte Touche Tohmatsu's inaugural Biotechnology Index. Copyright1999 Australian Biotechnology Association Ltd.
